BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 26172396)

  • 21. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients.
    Duchnowska R; Jassem J; Goswami CP; Dundar M; Gökmen-Polar Y; Li L; Woditschka S; Biernat W; Sosińska-Mielcarek K; Czartoryska-Arłukowicz B; Radecka B; Tomasevic Z; Stępniak P; Wojdan K; Sledge GW; Steeg PS; Badve S
    J Neurooncol; 2015 Mar; 122(1):205-16. PubMed ID: 25559688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
    Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
    J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
    Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
    JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences in Genomic Alterations Between Brain Metastases and Primary Tumors.
    Dono A; Takayasu T; Yan Y; Bundrant BE; Arevalo O; Lopez-Garcia CA; Esquenazi Y; Ballester LY
    Neurosurgery; 2021 Feb; 88(3):592-602. PubMed ID: 33369669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic profiling using the UltraSEEK panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival.
    Giannoudis A; Sartori A; Eastoe L; Zakaria R; Charlton C; Hickson N; Platt-Higgins A; Rudland PS; Irwin D; Jenkinson MD; Palmieri C
    Breast Cancer Res Treat; 2021 Nov; 190(2):241-253. PubMed ID: 34499316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2).
    Hechtman JF; Liu W; Sadowska J; Zhen L; Borsu L; Arcila ME; Won HH; Shah RH; Berger MF; Vakiani E; Shia J; Klimstra DS
    Mod Pathol; 2015 Aug; 28(8):1123-9. PubMed ID: 25975284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer.
    Verschoor N; Smid M; Jager A; Sleijfer S; Wilting SM; Martens JWM
    Breast Cancer Res; 2023 Nov; 25(1):145. PubMed ID: 37968696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients.
    Berghoff AS; Bartsch R; Preusser M; Ricken G; Steger GG; Bago-Horvath Z; Rudas M; Streubel B; Dubsky P; Gnant M; Fitzal F; Zielinski CC; Birner P
    Breast; 2014 Oct; 23(5):637-43. PubMed ID: 25017122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
    Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
    Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
    Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
    Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
    Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
    Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
    Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
    Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Roles of human epidermal growth factor receptor family in pulmonary lymphangioleiomyomatosis.
    Kobayashi K; Miki Y; Saito R; Adachi K; Seyama K; Okada Y; Sasano H
    Hum Pathol; 2018 Nov; 81():121-130. PubMed ID: 30030119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population.
    Lu Q; Wang N; Jiang K; Zhou H; Zhang P; Zhang J; Wang S; Sun P; Xu F
    ESMO Open; 2024 Mar; 9(3):102389. PubMed ID: 38460250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
    Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
    Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer.
    Da Silva L; Simpson PT; Smart CE; Cocciardi S; Waddell N; Lane A; Morrison BJ; Vargas AC; Healey S; Beesley J; Pakkiri P; Parry S; Kurniawan N; Reid L; Keith P; Faria P; Pereira E; Skalova A; Bilous M; Balleine RL; Do H; Dobrovic A; Fox S; Franco M; Reynolds B; Khanna KK; Cummings M; Chenevix-Trench G; Lakhani SR
    Breast Cancer Res; 2010; 12(4):R46. PubMed ID: 20604919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases.
    Schrijver WAME; Selenica P; Lee JY; Ng CKY; Burke KA; Piscuoglio S; Berman SH; Reis-Filho JS; Weigelt B; van Diest PJ; Moelans CB
    Cancer Res; 2018 Jun; 78(12):3112-3121. PubMed ID: 29615433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of ERBB family mRNA expression in breast carcinomas.
    Bièche I; Onody P; Tozlu S; Driouch K; Vidaud M; Lidereau R
    Int J Cancer; 2003 Sep; 106(5):758-65. PubMed ID: 12866037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
    Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
    Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.